AXIONOVA provides restricted access to verified compounds, AXIS governed delivery infrastructure, CDM cartridges, SENSE physiology streaming, and structured biological systems for licensed practitioners and qualified research entities.
Access is credentialed. Every partner account is reviewed for licensure, institutional context, intended research use, operational readiness, and chain-of-custody requirements. AXIONOVA does not sell directly to patients or consumers.
AXIONOVA distributes through verified medical, clinical, and research partners. Eligibility depends on professional credentials, institutional oversight, use context, and the ability to maintain controlled records.
The most-asked questions from licensed practitioners, research entities, and clinical operations leads applying for AXIONOVA access.
AXIONOVA requires professional credentials, license or NPI information where applicable, institutional affiliation, entity details, and intended research context. Research entities may be asked for oversight documentation or IRB-related materials depending on use case.
Most complete applications are reviewed within 24 to 48 hours. Institutional reviews, incomplete files, or documentation-dependent applications may take longer.
No. AXIONOVA does not sell directly to patients or consumers. Access is managed through verified practitioner and qualified research channels.
Yes. AXIONOVA provides ALETHRA-governed documentation for identity, lot records, certificate materials, release records, and chain-of-custody events where applicable.
AXIS is available through governed partner workflows. The device uses disposable CDM cartridges, NFC cartridge identity, BLE 5.3 event records, manual dose selection, electronic verification, and ALETHRA authorization controls.
Yes. ALETHA AI coaching, protocol personalization, diet programming, guided education, and 24/7 support are active and operational. ALETHRA governance is also active and remains the platform layer for identity, authorization, compliance, and event records.